Marc E Rothenberg Selected Research

Interleukin-5 (Interleukin 5)

1/2022	Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
1/2017	CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production.
1/2016	A hidden residential cell in the lung.
10/2014	IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation.
6/2014	Carbonic anhydrase IV is expressed on IL-5-activated murine eosinophils.
1/2014	Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil development.
2/2013	The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
2/2012	Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
1/2011	A striking local esophageal cytokine expression profile in eosinophilic esophagitis.
8/2010	Indoor insect allergens are potent inducers of experimental eosinophilic esophagitis in mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc E Rothenberg Research Topics

Disease

70	Eosinophilic Esophagitis 01/2022 - 03/2002
64	Inflammation (Inflammations) 03/2022 - 02/2003
55	Eosinophilia 01/2022 - 02/2002
40	Asthma (Bronchial Asthma) 01/2020 - 06/2002
23	Hypersensitivity (Allergy) 01/2019 - 06/2002
13	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022 - 01/2004
11	Hyperplasia 01/2016 - 11/2003
9	Food Hypersensitivity (Food Allergy) 01/2018 - 04/2008
8	Mastocytosis 01/2016 - 12/2003
8	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2012 - 06/2002
7	Atopic Dermatitis (Atopic Eczema) 01/2020 - 07/2006
7	Fibrosis (Cirrhosis) 12/2018 - 09/2006
6	Infections 01/2021 - 01/2005
6	Neoplasms (Cancer) 10/2017 - 07/2002
6	Esophagitis 01/2017 - 11/2006
5	COVID-19 01/2022 - 01/2020
5	Anaphylaxis (Anaphylactic Shock) 10/2015 - 03/2005
5	Respiratory Hypersensitivity 04/2011 - 04/2005
5	Pneumonia (Pneumonitis) 05/2007 - 10/2004
4	Deglutition Disorders (Dysphagia) 01/2020 - 06/2015
4	Diarrhea 04/2016 - 12/2003
4	Gastroesophageal Reflux (GERD) 05/2015 - 11/2006
4	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 09/2008 - 11/2003
3	Eosinophilic enteropathy 01/2021 - 01/2020
3	Lung Diseases (Lung Disease) 01/2020 - 11/2003
3	Disease Susceptibility (Diathesis) 01/2018 - 02/2006
3	Parasitic Diseases (Parasitic Disease) 08/2014 - 01/2004
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2011 - 11/2008
3	Insulin Resistance 02/2009 - 07/2006
3	Metaplasia 12/2006 - 09/2006
2	Cardiomegaly (Heart Hypertrophy) 12/2018 - 05/2006
2	Obesity 01/2017 - 04/2010
2	Hypertrophy 10/2015 - 12/2006
2	Systemic Mastocytosis 01/2014 - 09/2008
2	Allergic Rhinitis 07/2013 - 07/2006
2	Colitis 08/2010 - 12/2008

Drug/Important Bio-Agent (IBA)

42	AllergensIBA 01/2022 - 03/2002
38	Interleukin-13IBA 01/2021 - 06/2002
27	CytokinesIBA 01/2020 - 06/2002
26	Interleukin-5 (Interleukin 5)IBA 01/2022 - 02/2002
20	AntigensIBA 01/2021 - 02/2003
14	Interleukin-4 (Interleukin 4)IBA 01/2020 - 06/2003
14	ChemokinesIBA 10/2015 - 02/2003
13	Immunoglobulin E (IgE)IBA 01/2020 - 02/2003
12	Chemokine CCL11IBA 03/2016 - 11/2003
12	OvalbuminIBA 09/2015 - 10/2003
11	Biomarkers (Surrogate Marker)IBA 11/2021 - 11/2006
11	Chemokine CCL26IBA 05/2015 - 02/2006
10	Messenger RNA (mRNA)IBA 01/2022 - 06/2003
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2005
9	Proton Pump InhibitorsIBA 01/2021 - 06/2012
8	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2013
8	MicroRNAs (MicroRNA)IBA 12/2018 - 04/2009
8	CollagenIBA 07/2010 - 10/2004
7	mepolizumabIBA 01/2022 - 01/2004
7	ArginaseIBA 05/2012 - 06/2003
6	Interleukin-33IBA 10/2021 - 02/2013
6	GlucocorticoidsIBA 01/2017 - 12/2007
6	Chemokine CCL24IBA 07/2010 - 11/2003
5	Biological ProductsIBA 01/2022 - 07/2006
5	Pharmaceutical PreparationsIBA 10/2021 - 01/2004
5	ResistinIBA 09/2015 - 07/2006
5	Chemotactic FactorsIBA 10/2009 - 02/2003
4	Serine Proteases (Serine Protease)IBA 10/2021 - 10/2020
4	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 04/2016
4	AcidsIBA 01/2018 - 01/2012
4	InterleukinsIBA 05/2016 - 06/2002
4	Fluticasone (Cutivate)FDA LinkGeneric 08/2014 - 07/2004
4	Arginine (L-Arginine)FDA Link 06/2010 - 10/2004
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2018
3	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 01/2022 - 11/2013
3	Monoclonal AntibodiesIBA 01/2021 - 03/2008
3	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2020 - 03/2005
3	CalpainIBA 01/2018 - 04/2016
3	Thymic Stromal LymphopoietinIBA 01/2018 - 07/2010
3	SteroidsIBA 03/2016 - 02/2007
3	Interleukin-9 (Interleukin 9)IBA 10/2015 - 04/2008
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2014 - 05/2006
3	Interleukin-17 (Interleukin 17)IBA 02/2013 - 03/2006
3	Interleukin-12 (IL 12)IBA 09/2011 - 04/2009
3	Immunoglobulins (Immunoglobulin)IBA 08/2010 - 09/2005
3	STAT6 Transcription FactorIBA 05/2007 - 02/2003
3	Histamine (Histamine Dihydrochloride)FDA Link 03/2005 - 02/2003
2	anti-IgE antibodiesIBA 01/2022 - 12/2003
2	reslizumabIBA 01/2022 - 02/2012
2	VaccinesIBA 01/2022 - 08/2003
2	dupilumabIBA 01/2022 - 01/2020
2	Ac-GQFR-kbtIBA 10/2021 - 05/2021
2	SerpinsIBA 01/2021 - 10/2020
2	cendakimabIBA 01/2021 - 01/2019
2	LigandsIBA 01/2019 - 10/2005
2	Tryptases (Tryptase)IBA 12/2016 - 07/2010
2	AntibodiesIBA 04/2016 - 03/2005
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2015 - 02/2013
2	Neutralizing AntibodiesIBA 02/2012 - 08/2006
2	Cytokine Receptors (Cytokine Receptor)IBA 03/2011 - 10/2006
2	Immunoglobulin G (IgG)IBA 12/2010 - 03/2005

Therapy/Procedure

30	Therapeutics 03/2022 - 01/2004
2	Ambulatory Care (Outpatient Care) 01/2022 - 01/2022
2	Precision Medicine 01/2022 - 01/2018